Literature DB >> 476667

Distribution of radiolabeled alloantibodies in mice bearing 3-methylcholanthrene-induced sarcoma.

D J Buchsbaum, P C Walker, E A Johnson.   

Abstract

The distribution of purified 125I-labeled alloantibodies, prepared from the serum of DBA/2J mice obtained after immunization with C3H/HeJ spleen cells, was studied in immunosuppressed DBA/2J mice bearing either allogeneic C3H/HeJ 3-methylcholanthrene sarcomas growing s.c. or syngeneic SaD2 3-methylcholanthrene sarcomas. Once purified radiolabeled antibody was isolated from 125I-labeled immune gamma-globulin by a single adsorption onto C3H/HeJ RBC and elution from stroma prepared from these cells, by using 0.1 M glycine buffer (pH 3.0). Twice-purified alloantibody was then produced by Bio-Gel P-200 or Sephadex G-200 gel filtration chromatography or DEAE A-50 ion-exchange chromatography. In vitro, such purified antibodies bound specifically to C3H/HeJ RBC. In vivo, they localized to a significant extent following i.p. injection, preferentially in C3H/HeJ 3-methylcholanthrene sarcomas (4.4 to 8.9% of the injected dose per g of tumor equal to 1% of mouse weight), with mean tumor/blood ratios of 4.0 to 7.8, at 24 or 48 hr after injection. The percentage of injected dose localized in tumor and the tumor/blood ratio did not show significant differences with respect to time or method of antibody purification. Normal tissue/blood ratios in C3H/HeJ or SaD2 sarcoma-bearing mice were less than 0.9. The tumor/blood ratios in SaD2 sarcomas were approximately 0.6. Injection of 131I-labeled normal DBA/2J gamma-globulin resulted in normal tissue/blood and tumor/blood ratios of less than 0.9 in C3H/HeJ tumor-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476667

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  1 in total

1.  Unraveling the Cellular Mechanism of Assembling Cholesterols for Selective Cancer Cell Death.

Authors:  Huaimin Wang; Zhaoqianqi Feng; Cuihong Yang; Jinjian Liu; Jamie E Medina; S Ali Aghvami; Daniela M Dinulescu; Jianfeng Liu; Seth Fraden; Bing Xu
Journal:  Mol Cancer Res       Date:  2018-12-14       Impact factor: 5.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.